Comment | Published:

Cochrane corner: why we still don’t know whether anti-TNF biologic therapies impact uveitic macular oedema

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Barry RJ, Tallouzi MO, Bucknall N, Mathers JM, Murray PI, Calvert MJ, et al. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database Syst Rev. 2018;12:CD012577.

  2. 2.

    Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Int J Ophthalmol. 2004;218:223–36.

  3. 3.

    Williams GJ, Brannan S, Forrester JV, Gavin MP, Paterson-Brown SP, Purdie AT, et al. The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol. 2007;91:33–6.

  4. 4.

    Abdulaal MR, Abiad BH, Hamam RN. Uveitis in the aging eye: incidence, patterns, and differential diagnosis. J Ophthalmol. 2015;509456.

  5. 5.

    Rao NA. Uveitis in developing countries. Indian J Ophthalmol. 2013;61:253–4.

  6. 6.

    Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;121:588–95e1.

  7. 7.

    Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6.

  8. 8.

    Denniston AK, Dick AD. Systemic therapies for inflammatory eye disease: past, present and future. BMC Ophthalmol. 2013;13:18.

  9. 9.

    National Institute for Health and Clinical Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis: Technology appraisal guidance [TA460]. 2017. https://www.nice.org.uk/guidance/ta460. Accessed 9 April 2019.

  10. 10.

    Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–92.

  11. 11.

    Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–43.

  12. 12.

    Holland GN, Eydelman MB, Cunningham B, Chambers WA. Food and drug administration procedures for new drug and device approvals. Am J Ophthalmol. 2016;161:1–3.

  13. 13.

    Dean S, Mathers JM, Calvert M, Kyte DG, Conroy D, Folkard A, et al. “The patient is speaking”: discovering the patient voice in ophthalmology. Br J Ophthalmol. 2017;101:700–8.

  14. 14.

    Braithwaite T, Calvert M, Gray A, Pesudovs K, Denniston AK. The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas. 2019;10:9–24.

  15. 15.

    United States Food and Drug Administration. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD: Office of Communications, Division of Drug Information. Center for Drug Evaluation and Research. Food and Drug Administration. 20993-00022009. https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed 9 April 2019.

Download references

Author information

Conflict of interest

TB is part-funded by patient charity Olivia’s Vision and is a Cochrane Eyes and Vision Contact Editor. The remaining authors declare that they have no conflict of interest.

Correspondence to Tasanee Braithwaite.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark